Procter & Gamble Drops Out Of Somaxon's OTC Silenor Effort

Law360, New York (April 3, 2012, 8:21 PM EDT) -- Procter & Gamble Distributing Co. LLC has chosen not to move forward with branded prescription drug company Somaxon Pharmaceuticals Inc. on the development of an over-the-counter version of its insomnia drug Silenor, Somaxon said Tuesday.

The two companies agreed in November to evaluate the potential to develop and commercialize the doxepin-based product. Their agreement included jointly developing a desired product profile and conducting market research at P&G’s expense, according to a November U.S. Securities and Exchange Commission filing from Somaxon.

With P&G opting out of the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.